S. Yamayoshi, S. Ohka, K. Fujii, and S. Koike, Functional Comparison of SCARB2 and PSGL1 as Receptors for Enterovirus 71, Journal of Virology, vol.87, issue.6, pp.3335-3347, 2013.
DOI : 10.1128/JVI.02070-12

C. Poh, C. Sam, I. Chan, and Y. , Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor, J Virol, vol.87, pp.611-620, 2013.

N. Du, H. Cong, and H. Tian, Cell Surface Vimentin Is an Attachment Receptor for Enterovirus 71, Journal of Virology, vol.88, issue.10, pp.5816-5833, 2014.
DOI : 10.1128/JVI.03826-13

M. Ooi, S. Wong, P. Lewthwaite, M. Cardosa, and T. Solomon, Clinical features, diagnosis, and management of enterovirus 71, The Lancet Neurology, vol.9, issue.11, pp.1097-1105, 2010.
DOI : 10.1016/S1474-4422(10)70209-X

P. Plevka, R. Perera, M. Yap, J. Cardosa, R. Kuhn et al., Structure of human enterovirus 71 in complex with a capsid-binding inhibitor, Proceedings of the National Academy of Sciences, vol.110, issue.14, pp.5463-5467, 2013.
DOI : 10.1073/pnas.1222379110

A. Palma, I. Vliegen, E. De-clercq, and J. Neyts, Selective inhibitors of picornavirus replication, Medicinal Research Reviews, vol.18, issue.Pt 1, pp.823-884, 2008.
DOI : 10.1002/med.20125

X. Zhang, Z. Song, and B. Qin, Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection model, Antiviral Research, vol.97, issue.3, pp.264-269, 2013.
DOI : 10.1016/j.antiviral.2012.12.029

G. Lu, J. Qi, and Z. Chen, Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design, Journal of Virology, vol.85, issue.19, pp.10319-10331, 2011.
DOI : 10.1128/JVI.00787-11
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196414

G. Zhang, F. Zhou, and B. Gu, In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection, Archives of Virology, vol.60, issue.4, pp.669-679, 2012.
DOI : 10.1007/s00705-011-1222-6

H. Pourianfar, C. Poh, J. Fecondo, and L. Grollo, In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71, Virus Research, vol.169, issue.1, pp.22-29, 2012.
DOI : 10.1016/j.virusres.2012.06.025

W. Yorke, THE TREATMENT OF KALA-AZAR BY "BAYER 205.", BMJ, vol.1, issue.3244, p.370, 1923.
DOI : 10.1136/bmj.1.3244.370

S. Faust, C. Woodrow, and S. Patel, Sleeping Sickness in Brothers in London, The Pediatric Infectious Disease Journal, vol.23, issue.9, pp.879-881, 2004.
DOI : 10.1097/01.inf.0000137587.80399.3b

E. Lam, J. Au, and G. Otterson, Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, vol.686, issue.6, pp.1019-1029, 2010.
DOI : 10.1007/s00280-010-1252-x

K. Jentsch, G. Hunsmann, H. Hartmann, and P. Nickel, Inhibition of Human Immunodeficiency Virus Type I Reverse Transcriptase by Suramin-related Compounds, Journal of General Virology, vol.68, issue.8, pp.2183-2192, 1987.
DOI : 10.1099/0022-1317-68-8-2183

W. Offensperger, S. Offensperger, E. Walter, H. Blum, and W. Gerok, Suramin prevents duck hepatitis B virus infection in vivo., Antimicrobial Agents and Chemotherapy, vol.37, issue.7, pp.1539-1542, 1993.
DOI : 10.1128/AAC.37.7.1539

W. Xu, C. Liu, and L. Yan, Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications, Virology Journal, vol.9, issue.1, p.8, 2012.
DOI : 10.1128/JVI.00434-09

J. Liu, Y. Yang, Y. Xu, C. Ma, C. Qin et al., Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication, Virology Journal, vol.8, issue.1, p.483, 2011.
DOI : 10.1016/0168-1702(95)00087-9

Y. Zhang, W. Cui, and L. Liu, Pathogenesis study of enterovirus 71 infection in rhesus monkeys, Laboratory Investigation, vol.83, issue.9, pp.1337-1350, 2011.
DOI : 10.1111/j.1574-6976.2002.tb00601.x

L. Liu, Y. Zhang, and J. Wang, Study of the Integrated Immune Response Induced by an Inactivated EV71 Vaccine, PLoS ONE, vol.13, issue.1, p.54451, 2013.
DOI : 10.1371/journal.pone.0054451.s003

T. Haselhorst, J. Garcia, and T. Islam, Avian Influenza H5-Containing Virus-Like Particles (VLPs): Host-Cell Receptor Specificity by STD NMR Spectroscopy, Angewandte Chemie International Edition, vol.6, issue.10, pp.1910-1912, 2008.
DOI : 10.1002/anie.200704872
URL : https://hal.archives-ouvertes.fr/pasteur-00588962

T. Haselhorst, F. Fleming, and J. Dyason, Sialic acid dependence in rotavirus host cell invasion, Nature Chemical Biology, vol.367, issue.2, pp.91-93, 2009.
DOI : 10.1038/nchembio.134

N. Nagata, T. Iwasaki, and Y. Ami, Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation, Journal of General Virology, vol.85, issue.10, pp.2981-2989, 2004.
DOI : 10.1099/vir.0.79883-0

L. Liu, H. Zhao, and Y. Zhang, Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection, Virology, vol.412, issue.1, pp.91-100, 2011.
DOI : 10.1016/j.virol.2010.12.058

C. Vanchieri, A. Butler, and A. Knutsen, Addressing the barriers to pediatric drug development: workshop summary, 2008.

C. Chong, D. Sullivan, and . Jr, New uses for old drugs, Nature, vol.34, issue.7154, pp.645-646, 2007.
DOI : 10.1038/448645a

S. Kappagoda, U. Singh, and B. Blackburn, Antiparasitic Therapy, Mayo Clinic Proceedings, vol.86, issue.6, pp.561-583, 2011.
DOI : 10.4065/mcp.2011.0203

M. Panosian and C. , Human antiprotozoal therapy: past, present, and future, Clin Microbiol Rev, vol.8, pp.427-439, 1995.

M. , R. E. Sartor, O. Dahut, W. Figg, and W. , Suramin's development: what did we learn?, Invest New Drugs, vol.20, pp.209-219, 2002.

H. Scher, D. Jodrell, and J. Iversen, Use of adaptive control with feedback to individualize suramin dosing, Cancer Res, vol.52, pp.64-70, 1992.

C. Bowden, W. Figg, and N. Dawson, A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response, Cancer Chemotherapy and Pharmacology, vol.39, issue.1-2, pp.1-8, 1996.
DOI : 10.1007/s002800050531

M. Lustberg, S. Pant, and A. Ruppert, Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes, Cancer Chemotherapy and Pharmacology, vol.26, issue.10, pp.49-56, 2012.
DOI : 10.1007/s00280-012-1887-x

N. Nagata, H. Shimizu, and Y. Ami, Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71, Journal of Medical Virology, vol.17, issue.2, pp.207-216, 2002.
DOI : 10.1002/jmv.2209

R. Altmeyer, Virus Attachment and Entry Offer Numerous Targets for Antiviral Therapy, Current Pharmaceutical Design, vol.10, issue.30, pp.3701-3712, 2004.
DOI : 10.2174/1381612043382729

K. Vercauteren, G. Leroux-roels, and P. Meuleman, Blocking HCV entry as potential antiviral therapy, Future Virology, vol.7, issue.6, pp.547-561, 2012.
DOI : 10.2217/fvl.12.47

F. Curreli, S. Choudhury, and I. Pyatkin, Design, Synthesis, and Antiviral Activity of Entry Inhibitors That Target the CD4-Binding Site of HIV-1, Journal of Medicinal Chemistry, vol.55, issue.10, pp.4764-4775, 2012.
DOI : 10.1021/jm3002247

A. Webster, Pleconaril???an advance in the treatment of enteroviral infection in immuno-compromised patients, Journal of Clinical Virology, vol.32, issue.1, pp.1-6, 2005.
DOI : 10.1016/j.jcv.2004.06.006

M. Arita, T. Wakita, and H. Shimizu, Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity, Journal of General Virology, vol.89, issue.10, pp.2518-2530, 2008.
DOI : 10.1099/vir.0.2008/002915-0

M. Zeitlinger, H. Derendorf, and J. Mouton, Protein Binding: Do We Ever Learn?, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3067-3074, 2011.
DOI : 10.1128/AAC.01433-10
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122431